10-year survival of pulmonary arterial hypertension associated with connective tissue disease: insights from a multicentre PAH registry.

"Disclosure statement : The authors have declared no conflicts of interest."

"Funding The study was supported by the National Key Research and Development Program of China (No. 2016YFC1304400), the China Key Research Projects of the 11th National Five-Year Development Plan (Project Number: 2006BAI01A07) and the China Key Research Projects of the 12th National Five-Year Development Plan (No. 2011BA11B17). Disclosure statement: The authors have declared no conflicts of interest."

"This study was derived from a Chinese national prospective registry of pulmonary arterial hypertension involving 34 tertiary medical centres. This study complies with the Declaration of Helsinki and the design of the study was described in detail recently [], the protocol of which has been approved by the Institutional Review Board of Fuwai Hospital (Approval No. 2009–208) and has also been registered on ClinicalTrials.gov (Identifier: NCT01417338). Patients who underwent right heart catheterization (RHC) within one month before or during the study enrolment period (i.e. August 2009 to December 2019) and met the criterion of ‘mean pulmonary arterial pressure (mPAP) ≥25 mmHg and pulmonary arterial wedge pressure (PAWP) ≤15 mmHg’ were consecutively enrolled. All enrolled patients had given written informed consent. CTD-PAH patients were included in further analysis, and details for the inclusion and exclusion criteria are shown in the available at Rheumatology online."